- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Odyssey Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.06. | Odyssey Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | Odyssey Therapeutics Inc: Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 564 | GlobeNewswire (Europe) | Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on... ► Artikel lesen | |
| 02.06. | Oppenheimer initiates Odyssey Therapeutics stock with outperform rating | 2 | Investing.com | ||
| 02.06. | TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline | 1 | Investing.com | ||
| 02.06. | JPMorgan initiates Odyssey Therapeutics stock rating at Overweight | 1 | Investing.com | ||
| 11.05. | Odyssey Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Odyssey Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| ODYSSEY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.05. | Autoimmune diseases biotech Odyssey Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 08.05. | Odyssey Therapeutics Prices Upsized IPO Of 15.50 Mln Shares At $18/shr | 730 | AFX News | WASHINGTON (dpa-AFX) - Odyssey Therapeutics Inc. announced the pricing of its upsized initial public offering of 15.50 million shares of common stock at $18.00 per share. The company has also... ► Artikel lesen | |
| 08.05. | Odyssey Therapeutics prices $304M IPO at $18 per share | 2 | Investing.com | ||
| 08.05. | Odyssey Therapeutics Inc: Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering | 212 | GlobeNewswire (Europe) | BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. ("Odyssey"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune... ► Artikel lesen | |
| 05.05. | Odyssey Therapeutics, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 04.05. | Autoimmune diseases biotech Odyssey Therapeutics sets terms for $225 million IPO, pricing this week | 1 | Renaissance Capital | ||
| 04.05. | Odyssey Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Autoimmune diseases biotech Odyssey Therapeutics refiles for a $100 million IPO | 2 | Renaissance Capital | ||
| 17.04. | Odyssey Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 16.03. | Odyssey Therapeutics appoints H Martin Seidel to Scientific Advisory Board | 1 | PMLiVE | ||
| 21.01. | Odyssey Therapeutics Appoints Jolie Siegel EVP and General Counsel | 1 | Contract Pharma | ||
| 10.09.25 | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs | 444 | GlobeNewswire (Europe) | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,130 | -0,97 % | Handelsvolumen bei Novavax-Optionen erreicht Mehrmonatshoch | ||
| PALATIN TECHNOLOGIES | 9,000 | +6,19 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,186 | -1,33 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -9,54 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,705 | -3,56 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,385 | -1,28 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,050 | 0,00 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 3,020 | +1,00 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 1,965 | 0,00 % | Palisade Bio, Inc.: Palisade Bio to Participate in the Leerink Partners Therapeutics Forum | ||
| ONCOLYTICS BIOTECH | 0,850 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,220 | -4,01 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| OMEROS | 8,260 | +2,48 % | Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return |
Das Unternehmen ODYSSEY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 17,760 Euro und damit +4,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ODYSSEY THERAPEUTICS INC finden Sie auf Wallstreet Online.